Published in J Virol on March 21, 2007
Epigenetic activation of unintegrated HIV-1 genomes by gut-associated short chain fatty acids and its implications for HIV infection. Proc Natl Acad Sci U S A (2009) 1.24
Signaling through Toll-like receptors induces murine gammaherpesvirus 68 reactivation in vivo. J Virol (2008) 1.14
Short- and medium-chain fatty acids exhibit antimicrobial activity for oral microorganisms. Arch Oral Biol (2011) 0.98
Activation of PI3K/AKT and ERK MAPK signal pathways is required for the induction of lytic cycle replication of Kaposi's sarcoma-associated herpesvirus by herpes simplex virus type 1. BMC Microbiol (2011) 0.90
Short-chain fatty acids from periodontal pathogens suppress histone deacetylases, EZH2, and SUV39H1 to promote Kaposi's sarcoma-associated herpesvirus replication. J Virol (2014) 0.87
Activation and repression of Epstein-Barr Virus and Kaposi's sarcoma-associated herpesvirus lytic cycles by short- and medium-chain fatty acids. J Virol (2014) 0.81
Polymicrobial infection and bacterium-mediated epigenetic modification of DNA tumor viruses contribute to pathogenesis. MBio (2014) 0.77
Chromatinization of the KSHV Genome During the KSHV Life Cycle. Cancers (Basel) (2015) 0.77
Co-infections and Pathogenesis of KSHV-Associated Malignancies. Front Microbiol (2016) 0.76
Virus reactivation: a panoramic view in human infections. Future Virol (2011) 0.76
Bacterial Short Chain Fatty Acids Push All The Buttons Needed To Reactivate Latent Viruses. Stem Cell Epigenet (2015) 0.75
Impact of periodontal intervention on local inflammation, periodontitis, and HIV outcomes. Oral Dis (2016) 0.75
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science (1994) 39.60
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med (1995) 21.16
Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med (1996) 12.11
Persisting oncogenic herpesvirus induced by the tumour promotor TPA. Nature (1978) 9.25
Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J Virol (1998) 4.62
A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus. J Virol (1998) 4.23
Sodium butyrate inhibits histone deacetylation in cultured cells. Cell (1978) 4.20
Inhibition of histone deacetylase activity by butyrate. J Nutr (2003) 3.84
Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. N Engl J Med (1996) 3.61
n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature (1977) 3.60
Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Invest (2004) 3.39
Rapid diagnosis of anaerobic infections by direct gas-liquid chromatography of clinical speciments. J Clin Invest (1976) 3.34
The effect of sodium butyrate on histone modification. Cell (1978) 2.73
Charting latency transcripts in Kaposi's sarcoma-associated herpesvirus by whole-genome real-time quantitative PCR. J Virol (2002) 2.71
Butyrate suppression of histone deacetylation leads to accumulation of multiacetylated forms of histones H3 and H4 and increased DNase I sensitivity of the associated DNA sequences. Proc Natl Acad Sci U S A (1978) 2.70
The Kaposi sarcoma-associated herpesvirus (KSHV) is present as an intact latent genome in KS tissue but replicates in the peripheral blood mononuclear cells of KS patients. J Exp Med (1996) 2.67
Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8). J Gen Virol (1998) 2.34
Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. J Biol Chem (1978) 2.16
Inflammatory cytokines and the reactivation of Kaposi's sarcoma-associated herpesvirus lytic replication. Virology (2000) 1.93
Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood (2001) 1.83
Transmissible Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in saliva of men with a history of Kaposi's sarcoma. J Virol (1997) 1.76
Chromatin remodeling of the Kaposi's sarcoma-associated herpesvirus ORF50 promoter correlates with reactivation from latency. J Virol (2003) 1.70
Activation of latent Kaposi's sarcoma-associated herpesvirus by demethylation of the promoter of the lytic transactivator. Proc Natl Acad Sci U S A (2001) 1.65
Pathogenesis of AIDS-associated Kaposi's sarcoma. Hematol Oncol Clin North Am (1991) 1.45
Kaposi's sarcoma-associated herpesvirus induction of AP-1 and interleukin 6 during primary infection mediated by multiple mitogen-activated protein kinase pathways. J Virol (2005) 1.38
Induction of human herpesvirus-8 DNA replication and transcription by butyrate and TPA in BCBL-1 cells. J Gen Virol (1999) 1.37
Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation. Nucleic Acids Res (2000) 1.28
Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle. J Virol (2002) 1.23
Human immunodeficiency virus replication in a primary effusion lymphoma cell line stimulates lytic-phase replication of Kaposi's sarcoma-associated herpesvirus. J Virol (1999) 1.12
Wild-type Kaposi's sarcoma-associated herpesvirus isolated from the oropharynx of immune-competent individuals has tropism for cultured oral epithelial cells. J Virol (2004) 1.11
Molecular evidence of organ-related transmission of Kaposi sarcoma-associated herpesvirus or human herpesvirus-8 in transplant patients. Blood (2000) 1.05
Volatile fatty acids, metabolic by-products of periodontopathic bacteria, inhibit lymphocyte proliferation and cytokine production. J Dent Res (1995) 1.04
Relationship between herpesviruses and adult periodontitis and periodontopathic bacteria. J Periodontol (1999) 1.04
Suppression of tetradecanoyl phorbol acetate-induced lytic reactivation of Kaposi's sarcoma-associated herpesvirus by K1 signal transduction. J Virol (2002) 1.02
12-O-tetradecanoylphorbol-13-acetate induces Epstein-Barr virus reactivation via NF-kappaB and AP-1 as regulated by protein kinase C and mitogen-activated protein kinase. Virology (2001) 1.02
Short-chain carboxylic acid concentration in human gingival crevicular fluid. J Dent Res (1997) 1.01
Role of protein kinase C delta in reactivation of Kaposi's sarcoma-associated herpesvirus. J Virol (2004) 0.96
The bisindolylmaleimide GF 109203X, a selective inhibitor of protein kinase C, does not inhibit the potentiating effect of phorbol ester on ethanol-induced phospholipase C-mediated hydrolysis of phosphatidylethanolamine. Biochim Biophys Acta (1995) 0.96
DNA probe detection of periodontopathogens in advanced periodontitis. Scand J Dent Res (1993) 0.95
Volatile fatty acid, metabolic by-product of periodontopathic bacteria, induces apoptosis in WEHI 231 and RAJI B lymphoma cells and splenic B cells. Infect Immun (1998) 0.91
Molecular mediators of Porphyromonas gingivalis-induced T-cell apoptosis. Oral Microbiol Immunol (2002) 0.90
Dynamic changes in histone H3 phosphoacetylation during early embryonic stem cell differentiation are directly mediated by mitogen- and stress-activated protein kinase 1 via activation of MAPK pathways. J Biol Chem (2006) 0.89
Gas-liquid chromatography of the gingival fluid as an aid in periodontal diagnosis. J Periodontal Res (1985) 0.89
Phosphorylation at serine 28 and acetylation at lysine 9 of histone H3 induced by trichostatin A. Oncogene (2003) 0.88
Herpesviruses 6, 7 and 8 in HIV- and non-HIV-associated periodontitis. J Periodontal Res (2000) 0.87
Studies on the phosphorylation of protein kinase B by Ca(2+)/calmodulin-dependent protein kinases. J Biochem (2000) 0.79
A bactericidal effect for human lactoferrin. Science (1977) 3.73
Ingestion of Streptococcus mutans induces secretory immunoglobulin A and caries immunity. Science (1976) 2.78
Bactericidal activity of human lactoferrin: sensitivity of a variety of microorganisms. Infect Immun (1980) 2.75
Selective induction of an immune response in human external secretions by ingestion of bacterial antigen. J Clin Invest (1978) 2.64
A novel mouse model to study the virulence of and host response to Porphyromonas (Bacteroides) gingivalis. Infect Immun (1991) 2.07
Interactions between Naegleria fowleri and Legionella pneumophila. Infect Immun (1985) 1.92
Naturally occurring secretory immunoglobulin A antibodies to Streptococcus mutans in human colostrum and saliva. Infect Immun (1976) 1.85
Positive coooperativity in the binding of Streptococcus sanguis to hydroxylapatite. Infect Immun (1982) 1.85
Bactericidal activity of human lactoferrin: differentiation from the stasis of iron deprivation. Infect Immun (1982) 1.67
Concept of the local and common mucosal immune response. Adv Exp Med Biol (1978) 1.46
Bactericidal activity of human lactoferrin: influence of physical conditions and metabolic state of the target microorganism. Infect Immun (1981) 1.35
Effects of a Porphyromonas gingivalis infection on inflammatory mediator response and pregnancy outcome in hamsters. Infect Immun (1994) 1.30
Identification of a novel protein encoded by the BamHI A region of the Epstein-Barr virus. J Virol (1997) 1.28
Inflammatory mediator response as a potential risk marker for periodontal diseases in insulin-dependent diabetes mellitus patients. J Periodontol (1997) 1.28
Secretory IgM antibodies to Streptococcus mutans in subjects with selective IgA deficiency. Clin Immunol Immunopathol (1977) 1.24
Differentiation and interaction of secretory immunoglobulin A and a calcium-dependent parotid agglutinin for several bacterial strains. Infect Immun (1987) 1.20
Influence of immunization on Porphyromonas gingivalis colonization and invasion in the mouse chamber model. Infect Immun (1992) 1.18
Phagocytosis of virulent Porphyromonas gingivalis by human polymorphonuclear leukocytes requires specific immunoglobulin G. Infect Immun (1991) 1.18
Bactericidal effect of lactoferrin on Legionella pneumophila. Infect Immun (1986) 1.18
Monocytic TNF alpha secretion patterns in IDDM patients with periodontal diseases. J Clin Periodontol (1997) 1.17
Superior leukocyte separation with a discontinuous one-step Ficoll-Hypaque gradient for the isolation of human neutrophils. J Immunol Methods (1988) 1.17
Killing of Actinobacillus actinomycetemcomitans by human lactoferrin. Infect Immun (1988) 1.13
The molecular epidemiology and evolution of Epstein-Barr virus: sequence variation and genetic recombination in the latent membrane protein-1 gene. J Infect Dis (1999) 1.12
Inhibition of C3 and IgG proteolysis enhances phagocytosis of Porphyromonas gingivalis. J Immunol (1993) 1.12
Direct interaction of Actinobacillus actinomycetemcomitans with normal and defective (LJP) neutrophils. J Periodontal Res (1987) 1.11
Hemin-induced modifications of the antigenicity and hemin-binding capacity of Porphyromonas gingivalis lipopolysaccharide. Infect Immun (1996) 1.08
Use of mutants in the elucidation of virulence of Streptococcus mutans. Adv Exp Med Biol (1978) 1.06
Effects of natural cross-linkers on the stability of dentin collagen and the inhibition of root caries in vitro. Caries Res (2008) 1.02
Glucose-6-phosphatase mutation G188R confers an atypical glycogen storage disease type 1b phenotype. Pediatr Res (2000) 1.01
The Epstein-Barr virus EBNA-2 gene in oral hairy leukoplakia: strain variation, genetic recombination, and transcriptional expression. J Virol (1994) 1.00
Separation of human IgA1 and IgA2 using jacalin-agarose chromatography. J Immunol Methods (1987) 1.00
Fluoride release from restorative materials and its effects on dentin demineralization. J Dent Res (1999) 0.99
Induction of secretory antibodies in humans following ingestion of Streptococcus mutans. Adv Exp Med Biol (1978) 0.99
Effects of Escherichia coli and Porphyromonas gingivalis lipopolysaccharide on pregnancy outcome in the golden hamster. Infect Immun (1994) 0.99
Specific activity of alpha1proteinase inhibitor and alpha2macroglobulin in human serum: application to insulin-dependent diabetes mellitus. Clin Immunol Immunopathol (1998) 0.98
Self antigen prognostic for human immunodeficiency virus disease progression. Clin Diagn Lab Immunol (2001) 0.96
Bactericidal effect of lactoferrin on Legionella pneumophila: effect of the physiological state of the organism. Can J Microbiol (1989) 0.94
Comparison fo agglutinin titers for Streptococcus mutans in tears, saliva, and serum. Infect Immun (1982) 0.93
Characterization of lactoferrin interaction with Streptococcus mutans. J Dent Res (1987) 0.93
Immune dysfunction and dental caries: a preliminary report. J Dent Res (1977) 0.92
Neutrophil function in localized juvenile periodontitis. Phagocytosis, superoxide production and specific granule release. J Periodontol (1986) 0.92
Stability and release of antiviral drugs from ethylene vinyl acetate (EVA) copolymer. J Mater Sci Mater Med (2006) 0.91
Protein kinase C inhibition by sphingoid long-chain bases: effects on secretion in human neutrophils. Arch Biochem Biophys (1987) 0.91
Effects of alpha-amylase on in vitro growth of Legionella pneumophila. Infect Immun (1983) 0.90
Effective immunity to dental caries: selective induction of secretory immunity by oral administration of Streptococcus mutans in rodents. Adv Exp Med Biol (1978) 0.90
Antibody-dependent alternate pathway of complement activation in opsonophagocytosis of Porphyromonas gingivalis. Infect Immun (1991) 0.90
Inhibition of HIV-1 by modification of a host membrane protease. Int Immunol (1995) 0.89
Secretory immunity and immunodeficiency. Adv Exp Med Biol (1978) 0.89
Bacteria-agglutinating characteristics of secretory IgA and a salivary agglutinin. Adv Exp Med Biol (1987) 0.89
Defective neutrophil function in an insulin-dependent diabetes mellitus patients. A case report. J Periodontol (1991) 0.88
Enhancement of Streptococcus mutans colonization by direct bonded orthodontic appliances. J Dent Res (1983) 0.87
Bactericidal activity of different forms of lactoferrin. Adv Exp Med Biol (1994) 0.86
Mechanisms of expression of HHV8, EBV and HPV in selected HIV-associated oral lesions. Oral Dis (2002) 0.85
Lactoferrin interaction with salmonellae potentiates antibiotic susceptibility in vitro. Diagn Microbiol Infect Dis (1994) 0.84
Effects of a combination therapy to eliminate Porphyromonas gingivalis in refractory periodontitis. J Periodontol (1993) 0.84
Changes in the localization of catalase during differentiation of neutrophilic granulocytes. Blood (1994) 0.82
Neutrophil defects and host-parasite interactions in the pathogenesis of localized juvenile periodontitis. Adv Dent Res (1988) 0.81
Epstein-Barr virus infection and expression in oral lesions. Oral Dis (1997) 0.81
A dynamic model for induced reactivation of latent virus. J Theor Biol (2006) 0.80
Effect of lactoferrin on interaction of Prevotella intermedia with plasma and subepithelial matrix proteins. Oral Microbiol Immunol (1994) 0.80
Kinetics of coaggregation of Porphyromonas gingivalis with Fusobacterium nucleatum using an automated microtiter plate assay. Oral Microbiol Immunol (2001) 0.78
A clinical study of bacterial contamination of chlorhexidine-coated filaments of an interdental brush. J Clin Dent (1998) 0.78
Polymicrobial infection and bacterium-mediated epigenetic modification of DNA tumor viruses contribute to pathogenesis. MBio (2014) 0.77
New clinical diagnostic strategies based on pathogenesis of disease. J Periodontal Res (1993) 0.77
Functional differences in human neutrophils isolated pre- and post-prandially. FEBS Lett (1991) 0.76
Equivalent mortality in normal and athymic mice infected with Naegleria fowleri. J Parasitol (1985) 0.76
Cofactor requirements for expression of lactoferrin bactericidal activity on enteric bacteria. Adv Exp Med Biol (1987) 0.75
Caries immunization through ingestion of Streptococcus mutans. Dent Abstr (1976) 0.75
Modulation of chronic enteric infection by distant oral infection. J Endod (1999) 0.75
Hydrogen peroxide inhibits glucose metabolism and collagen synthesis in bone. J Periodontol (1987) 0.75
Immunodeficiency disease and implications for dental treatment. J Am Dent Assoc (1982) 0.75